BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET
Company Participants
Traci McCarty - Vice President, Investor Relations
J.J. Bienaime - Chairman and Chief Executive Officer
Jeff Ajer - Executive Vice President and Chief Commercial Officer
Hank Fuchs - President, Worldwide Research and Development
Greg Guyer - Executive Vice President and Chief Technical Officer
Brian Mueller - Executive Vice President and Chief Financial Officer
Conference Call Participants
Salveen Richter - Goldman Sachs
Chris Raymond - Piper Sandler
Robyn Karnauskas - Truist
Cory Kasimov - JPMorgan
Paul Matteis - Stifel
Gena Wang - Barclays
Geoff Meacham - Bank of America
Phil Nadeau - Cowen
Matthew Harrison - Morgan Stanley
Joseph Schwartz - SVB Securities
Debjit Chattopadhyay - Guggenheim
Joel Beatty - Baird
Luca Issi - RBC Capital
Operator
Good day and thank you for standing by. Welcome to the BioMarin First Quarter 2022 Financial Results Conference Call. Hosting the conference call today from BioMarin is Traci McCarty, Group Vice President of Investor Relations. Please go ahead, Traci.
Traci McCarty
Thank you, Ashley. Thank you everyone for joining us today. To remind you, this non-confidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. including expectations regarding BioMarin’s financial performance, commercial products and potential future products in different areas of therapeutic research and development. Results may differ materially depending on the progress of BioMarin’s product programs, actions of regulatory authorities, availability of capital, future actions in the pharmaceutical market and developments by competitors and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, such as 10-Q, 10-K and 8-K report.
On the call today from BioMarin management are J.J. Bienaime, Chairman and Chief Executive Officer; Jeff Ajer, Executive Vice President, Chief Commercial Officer; Hank Fuchs, President, Worldwide Research and Development; Greg Guyer, Executive Vice President, Chief Technical Officer; and Brian Mueller, Executive Vice
- Read more current BMRN analysis and news
- View all earnings call transcripts